Prelude Therapeutics (PRLD) Resumen de Acciones
Prelude Therapeutics Incorporated, una empresa de oncología de precisión en fase clínica, se centra en el descubrimiento y desarrollo de nuevos medicamentos de precisión contra el cáncer para pacientes desatendidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 4/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
PRLD Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Prelude Therapeutics Incorporated
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$4.50 |
| Máximo en las últimas 52 semanas | US$5.54 |
| Mínimo de 52 semanas | US$0.75 |
| Beta | 1.1 |
| Cambio en 1 mes | -0.22% |
| Variación en 3 meses | 98.24% |
| Cambio de 1 año | 392.29% |
| Variación en 3 años | -12.79% |
| Variación en 5 años | -86.36% |
| Variación desde la OPV | -82.82% |
Noticias y actualizaciones recientes
Recent updates
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Shareholders might have noticed that Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) filed its first-quarter result...
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
Catalysts About Prelude Therapeutics Prelude Therapeutics is a clinical stage oncology company focused on discovering and developing precision cancer medicines. What are the underlying business or industry changes driving this perspective?Prelude Therapeutics Incorporated's (NASDAQ:PRLD) 66% Share Price Plunge Could Signal Some Risk
Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) shares have retraced a considerable 66% in the last month, reversing...Prelude Therapeutics: A Subtle Shift In Pipeline Underscores Funding Challenges
Summary Prelude Therapeutics continues to explore the SMARCA2 anticancer approach, with no major hiccups disclosed to date. A strategic shift from their main pipeline contender raises concerns about data not yet disclosed, however. PRLD's funding situation is also in doubt, as they will find themselves needing to raise cash in the coming months. An upcoming ASH presentation could also shed some light on the next steps for two preclinical projects in myeloproliferative neoplasms. Read the full article on Seeking AlphaPrelude Therapeutics (NASDAQ:PRLD) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
Summary Prelude Therapeutics once produced positive clinical data from a now abandoned program. The company's current lead candidates are PRT3789, a SMARCA2 inhibitor, and PRT2527, a CDK9 inhibitor, both in phase 1 trials. Both programs have early preclinical data and look scientifically interesting. However, they are too early to merit an investment right now, although they bear watching. Read the full article on Seeking AlphaHere's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Prelude wins FDA clearance to start Phase 1 trial for cancer candidate
Prelude Therapeutics (NASDAQ:PRLD), an oncology-focused biotech, announced Tuesday that the FDA cleared its Investigational New Drug Application (IND) for PRT3789 allowing the company to start a Phase 1 trial for the antitumor agent. A protein degrader targeted at SMARCA2 (BRM) mutations in cancer tissue, PRT3789, has demonstrated antitumor activity in preclinical models at well-tolerated doses, the company said. “Clearance of the IND for PRT3789 represents a major milestone for Prelude Therapeutics, as we advance our first-in-class SMARCA2 protein degrader from discovery to the clinic,” Dr. Peggy Scherle, Chief Scientific Officer of Prelude (PRLD), noted. The Phase 1 trial for PRT3789 is designed to enroll patients with advanced solid tumors harboring SMARCA4. The dosing is expected to start in Q1 2023. PRLD awaits multiple catalysts in its clinical programs this year.Prelude downgraded at Morgan Stanley ahead of key update
Prelude Therapeutics (NASDAQ:PRLD) inched lower on Friday after Morgan Stanley downgraded the cancer-focused biotech to Equal Weight from Overweight as the company plans to disclose key steps forward for its PRMT5 program, including the solid tumor candidate PRT811 in H2 2022. The analysts see upside potential as PRLD remains on track to report early findings from its MCL1 inhibitor program and CDK9 inhibitor program during the second half of 2022. However, they see better opportunities elsewhere in the coverage noting uncertainty over the path forward for PRT811. Morgan Stanley lowers the probability of success for PRT811 in GBM, solid tumors, and myeloid malignancies to 20% from 25%, in line with the range it usually uses for Phase 1 assets, and trims the price target for PRLD to $11 from $19. Early this year, PRLD decided to drop the development of the PRT543 candidate in its PRMT5 program and focus its efforts on PRT811.We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Rentabilidad de los accionistas
| PRLD | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -3.4% | -3.0% | -0.3% |
| 1Y | 392.3% | 32.9% | 26.7% |
Rentabilidad vs. Industria: PRLD superó a la industria US Biotechs, que obtuvo un rendimiento del 32.9% el año pasado.
Rentabilidad vs. Mercado: PRLD superó al mercado US, que obtuvo un rendimiento del 26.7% el año pasado.
Volatilidad de los precios
| PRLD volatility | |
|---|---|
| PRLD Average Weekly Movement | 17.8% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: El precio de las acciones de PRLD ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de PRLD ha disminuido de 28% a 18% en el último año, pero sigue siendo superior al 75% de los valores de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2016 | 79 | Kris Vaddi | preludetx.com |
Prelude Therapeutics Incorporated, una empresa de oncología de precisión en fase clínica, se centra en el descubrimiento y desarrollo de nuevos medicamentos de precisión contra el cáncer para pacientes desatendidos. Está desarrollando JAK2V617F, un producto con mutación impulsora para el tratamiento de neoplasias mieloproliferativas, mielofibrosis (MF), policitemia vera y trombocitemia esencial (ET); KAT6A para el tratamiento del cáncer de mama avanzado y otros tumores sólidos; y conjugados de anticuerpos degradadores de calreticulina mutada para tratar MF y ET. La empresa colabora con AbCellera Biologics para descubrir, desarrollar y comercializar nuevos conjugados de anticuerpos degradadores.
Resumen de fundamentos de Prelude Therapeutics Incorporated
| Estadísticas fundamentales de PRLD | |
|---|---|
| Capitalización bursátil | US$429.47m |
| Beneficios(TTM) | -US$77.80m |
| Ingresos (TTM) | US$16.72m |
¿Está PRLD sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de PRLD | |
|---|---|
| Ingresos | US$16.72m |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$16.72m |
| Otros gastos | US$94.52m |
| Beneficios | -US$77.80m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.77 |
| Margen bruto | 100.00% |
| Margen de beneficio neto | -465.30% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado PRLD a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 08:27 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Prelude Therapeutics Incorporated está cubierta por 6 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Reni Benjamin | Citizens JMP Securities, LLC |
| Jason Kolbert | D. Boral Capital LLC. |